GT Medical Technologies, a medical device company with the aim of improving the lives of patients with brain tumors, announced it has agreed to acquire substantially all of the radioactive Cesium-131 seed assets and related business infrastructure from Isoray Medical, which is a subsidiary of Perspective Therapeutics, Inc.. GT Medical Technologies' GammaTile Therapy is FDA-approved to treat patients with operable brain tumors to eliminate residual tumor cells. Full market release for this technology occurred in March 2020, and over 100 leading brain tumor treatment centers have adopted GammaTile to date. The transaction is expected to decrease the required lead times from the customer order to product delivery, allowing even more patients to benefit from this game-changing technology. The closing of the transaction is subject to satisfaction of customary conditions to closing, and it is expected to close in the first quarter of 2024.
To read more please visit:
Source: GT